APA (7th ed.) Citation

BD, S., RD, C., JH, P., R, H., AC, L., N, B., . . . OO, O. (2025). Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3. Leukemia, 39(5), 1058. https://doi.org/10.1038/s41375-025-02532-7

Chicago Style (17th ed.) Citation

BD, Shah, et al. "Three-year Analysis of Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Treated with Brexucabtagene Autoleucel in ZUMA-3." Leukemia 39, no. 5 (2025): 1058. https://doi.org/10.1038/s41375-025-02532-7.

MLA (9th ed.) Citation

BD, Shah, et al. "Three-year Analysis of Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia Treated with Brexucabtagene Autoleucel in ZUMA-3." Leukemia, vol. 39, no. 5, 2025, p. 1058, https://doi.org/10.1038/s41375-025-02532-7.